SR1078 is a newly described synthetic RORα/γ agonist. Treatment of cancer cells with SR1078 leads to p53 stabilization and induction of apoptosis. SR1078 modulates the conformation of RORγ in a biochemical assay and activates RORα and RORγ driven transcription. Furthermore, SR1078 stimulates expression of endogenous ROR target genes in HepG2 cells that express both RORα and RORγ. Pharmacokinetic studies indicate that SR1078 displays reasonable exposure following injection into mice, and consistent with SR1078 functioning as a RORα/RORγ agonist, expression of two ROR target genes, glucose-6-phosphatase and fibroblast growth factor 21, were stimulated in the liver. Thus, SR1078 can be utilized as a chemical tool to probe the function of these receptors both in vitro and in vivo.